References
Balls M, Combes RD (2005) Validation via weight of evidence approaches. ALTEX 23(special issue):332–335
Blaauboer BJ, Andersen ME (2007) The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch Toxicol 81:385–387. doi:10.1007/s00204-006-0175-0
Bolt HM, Hengstler JG (2008) Most cited articles in the Archives of Toxicology: the debate about possibilities and limitations of in vitro toxicity tests and replacement of in vivo studies. Arch Toxicol 82:881–883. doi:10.1007/s00204-008-0379-6
Bottini AA, Alepee N, Phillips B et al (2008) Optimisation of the post-validation process. The report and recommendations of ECVAM workshop 67. ATLA 36:353–366
Bouvier d’Yvoire M, Prieto P, Blaauboer B et al (2007) Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. ATLA 35:661–671
Clemedson C et al (1998) MEIC evaluation of acute systemic toxicity. Part IV. In vitro results from 67 toxicity assays used to test reference chemicals 31–50 and a comparative cytotoxicity analysis. ATLA 26:131–183
Clemedson C, Kolman A, Forsby A (2007) The Integrated Acute Systemic Toxicity project (ACuteTox) for the optimisation and validation of alternative in vitro tests. ATLA 35:33–38
Combes RD, Gaunt I, Balls M (2004) A scientific and animal welfare assessment of the OECD Health Effects Guidelines for the safety testing of chemicals under the EU REACH scheme. ATLA 32:163–208
Combes R, Balls M, Illing P et al (2006) Possibilities for a new approach to chemicals risk assessment—the report of a FRAME workshop. ATLA 34:621–649
Dierickx PJ (2005) Prediction of Human Acute Toxicity by the Hep G2/24-hour/Total Protein Assay, with Protein Measurement bythe CBQCA Method. ATLA 33:207–213
Ekwall B (1999) Overview of the final MEIC results. II: The in vitro–in vivo evaluation, including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans. Toxicol In Vitro 13:665–673. doi:10.1016/S0887-2333(99)00061-2
Flynn TJ, Ferguson MS (2008) Multiendpoint mechanistic profiling of hepatotoxicants in HepG2/C3A human hepatoma cells and novel statistical approaches for development of a prediction model for acute hepatotoxicity. Toxicol In Vitro 22:1618–1631. doi:10.1016/j.tiv.2008.04.016
Greim H (2007) Reply to the letter to the editor: the need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative, by B.J. Blaauboer and M.E. Andersen (Arch Toxicol 2007, 81: 385–387). Arch Toxicol (2007) 81:895–896
Greim H, Arand M, Autrup H, Bolt HM et al (2006) Toxicological comments to the discussion about REACH. Arch Toxicol 80:121–124. doi:10.1007/s00204-005-0039-z
Grindon C, Combes R et al (2008) An integrated decision-tree testing strategy for repeat dose toxicity with respect to the requirements of the EU REACH legislation. ATLA 36:93–101
Gülden M, Seibert H (2007) The improvement of in vitro cytotoxicity testing for the assessment of acute toxicity in fish. ATLA 35:39–46
Halle W (2003) The registry of cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals. ATLA 31:89–198
Hartung T, Bremer S, Casati S et al (2004) A Modular Approach to the ECVAM Principles on Test Validity. ATLA 32:467–472
Nielsen JB (2008) What you see may not always be what you get–Bioavailability and extrapolation from in vitro tests. Toxicol In Vitro 22:1038–1042. doi:10.1016/j.tiv.2007.12.013
O’Brien PJ, Irwin W, Diaz D et al (2006) High concordance of drug induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580–604. doi:10.1007/s00204-006-0091-3
OECD (2001). Draft Guidance Document on the Development, Validation and Regulatory Acceptance of New and Updated Internationally Acceptable Test Methods in Hazard Assessment, Environment Directorate, 43 pp. Paris, France: OECD
Sjöström M, Kolman A, Clemedson C, Clothier R (2008) Estimation of human blood LC50 values for use in modelling of in vitro–in vivo data of the ACuteTox project. Toxicol In Vitro 22:1405–1411. doi:10.1016/j.tiv.2008.04.017
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Combes, R.D. Some thoughts on the use of replacement alternatives for toxicity testing and risk assessment. Arch Toxicol 83, 199–201 (2009). https://doi.org/10.1007/s00204-009-0408-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-009-0408-0